US Stock Market Move | AstraZeneca PLC Sponsored ADR (AZN.US) rose more than 4% in pre-market trading, with core Q3 earnings per share exceeding expectations.

On Thursday, Astrazeneca PLC Sponsored ADR (AZN.US) rose over 4% in pre-market trading to $84.92. Astrazeneca PLC Sponsored ADR announced its third-quarter performance, with total revenue increasing 12% year-on-year to $15.91 billion, core earnings per share at $2.38, exceeding market expectations of $2.27. This was driven by strong sales of cancer and diabetes drugs. Revenue for the first nine months increased 10% year-on-year to $43.236 billion, with core earnings per share at $7.04. The company reaffirmed its guidance of achieving high single-digit revenue growth and low double-digit core earnings per share growth for the full year, in line with market expectations. The company plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year.